Get the Stockscreener App
4.12
3.06%
-0.13
Pre-market:
2.51
-1.61
-39.08%
Alpha Cognition Inc stock is traded at $4.12, with a volume of 64,822.
It is down -3.06% in the last 24 hours and down -27.59% over the past month.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
See More
Previous Close:
$4.25
Open:
$4.4
24h Volume:
64,822
Relative Volume:
0.84
Market Cap:
$77.37M
Revenue:
-
Net Income/Loss:
$-14.72M
P/E Ratio:
-1.4558
EPS:
-2.83
Net Cash Flow:
$-7.41M
1W Performance:
-1.20%
1M Performance:
-27.59%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.97
$4.8315
1-Week Range:
$3.97
$5.09
52-Week Range:
$3.75
$7.00
Alpha Cognition Inc Stock (ACOG) Company Profile
Name
Alpha Cognition Inc
Sector
Industry
Phone
(858) 344-4375
Address
1200-750 W PENDER ST, VANCOUVER
Compare ACOG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
4.12 | 77.37M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | H.C. Wainwright | Buy |
Alpha Cognition Inc Stock (ACOG) Latest News
Alpha Cognition Inc. Reports Strong 2024 Financials - TipRanks
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Alpha Cognition announces board changes - Investing.com Australia
Alpha Cognition announces board changes By Investing.com - Investing.com Canada
Alpha Cognition Appoints Robert Wills To Board - citybiz
Alpha Cognition Earnings Call: Positive Outlook Amid Growth - TipRanks
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - The Globe and Mail
Alpha Cognition stock hits 52-week low at $4.65 amid downturn - Investing.com Canada
HC Wainwright Expects Stronger Earnings for Alpha Cognition - Defense World
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 - TradingView
Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright - Defense World
Alpha Cognition Inc. (ACOG) reports earnings - Quartz
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
Earnings Scheduled For March 31, 2025 - Benzinga
Comparing Alpha Cognition (ACOG) and The Competition - Defense World
Alpha Cognition (NASDAQ:ACOG) Upgraded at Raymond James - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Alpha Cognition (ACOG) Projected to Release Quarterly Earnings on Wednesday - Defense World
HC Wainwright Predicts Alpha Cognition Q1 Earnings - MarketBeat
Rosalind Advisors Inc. Invests $1.49 Million in Alpha Cognition, Inc. (NASDAQ:ACOG) - MarketBeat
Alpha Cognition (NASDAQ:ACOG) Now Covered by HC Wainwright - MarketBeat
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - The Globe and Mail
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
90% Workforce Reduction Sent This Small Cap Soaring - The Globe and Mail
UNTHSC Names Permanent TCOM Dean and Alpha Cognition Commercializes Alzheimer's Drug - D Magazine
Alpha Cognition (NASDAQ:ACOG) Now Covered by Analysts at HC Wainwright - Defense World
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease - BioSpace
Alpha Cognition Launches Sales of Alzheimer’s Drug ZUNVEYL - dallasinnovates.com
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst - Benzinga
Alpha Cognition Inc.Common Stock (NQ: ACOG - FinancialContent
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - The Globe and Mail
Alpha Cognition Launches Zunveyl for Treating Alzheimer's Disease; Shares Up Pre-Bell - Marketscreener.com
HC Wainwright Initiates Alpha Cognition at Buy With $20 Price Target -March 18, 2025 at 07:07 am EDT - Marketscreener.com
HC Wainwright & Co. Initiates Coverage of Alpha Cognition (ACOG) with Buy Recommendation - Nasdaq
H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy - TradingView
Acetylcholinesterase Inhibitors Market is expected to reach - openPR
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Insider Monkey
Alpha Cognition sets new executive and director compensation By Investing.com - Investing.com Australia
Alpha Cognition Inc Stock (ACOG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alpha Cognition Inc Stock (ACOG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):